Neuroscientific Biopharmaceuticals Ltd (NSB) — Cash Flow-to-Debt Ratio
Neuroscientific Biopharmaceuticals Ltd (NSB) has a Cash Flow-to-Debt Ratio of -3.22x as of June 2025, meaning its operating cash flow of AU$-480.55K could theoretically repay -3% of its total liabilities (AU$149.22K) in one year. See Neuroscientific Biopharmaceuticals Ltd (NSB) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Neuroscientific Biopharmaceuticals Ltd Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Neuroscientific Biopharmaceuticals Ltd across 10 annual periods. Also explore Neuroscientific Biopharmaceuticals Ltd annual equity growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Neuroscientific Biopharmaceuticals Ltd (2016–2025)
Year-by-year debt coverage analysis for Neuroscientific Biopharmaceuticals Ltd. For market capitalisation and broader financial context, see NSB market cap.
| Year | CF-to-Debt Ratio | Operating CF (AUD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -6.31x | AU$-941.33K | AU$149.22K | ▼ -1321.5% |
| 2024 | 0.52x | AU$44.25K | AU$85.68K | ▲ +113.4% |
| 2023 | -3.86x | AU$-2.30 Million | AU$597.36K | ▼ -23.2% |
| 2022 | -3.13x | AU$-6.94 Million | AU$2.22 Million | ▲ +73.1% |
| 2021 | -11.64x | AU$-2.60 Million | AU$223.41K | ▲ +54.8% |
| 2020 | -25.77x | AU$-2.28 Million | AU$88.53K | ▼ -14.4% |
| 2019 | -22.53x | AU$-1.41 Million | AU$62.48K | ▼ -245.6% |
| 2018 | -6.52x | AU$-497.91K | AU$76.39K | ▼ -50.9% |
| 2017 | -4.32x | AU$-186.42K | AU$43.15K | ▼ -501.2% |
| 2016 | -0.72x | AU$-87.76K | AU$122.12K | — |